[go: up one dir, main page]

SG11202007221QA - Method of producing natural killer cells and composition for treating cancer - Google Patents

Method of producing natural killer cells and composition for treating cancer

Info

Publication number
SG11202007221QA
SG11202007221QA SG11202007221QA SG11202007221QA SG11202007221QA SG 11202007221Q A SG11202007221Q A SG 11202007221QA SG 11202007221Q A SG11202007221Q A SG 11202007221QA SG 11202007221Q A SG11202007221Q A SG 11202007221QA SG 11202007221Q A SG11202007221Q A SG 11202007221QA
Authority
SG
Singapore
Prior art keywords
composition
treating cancer
natural killer
killer cells
producing natural
Prior art date
Application number
SG11202007221QA
Inventor
Sang Woo Park
Yong Man Kim
Jae Seob Jung
Yong-Hee Rhee
Original Assignee
Nkmax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190001981A external-priority patent/KR102732845B1/en
Priority claimed from KR1020190001983A external-priority patent/KR102765799B1/en
Application filed by Nkmax Co Ltd filed Critical Nkmax Co Ltd
Priority claimed from PCT/US2019/016076 external-priority patent/WO2019152663A1/en
Publication of SG11202007221QA publication Critical patent/SG11202007221QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
SG11202007221QA 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer SG11202007221QA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20180012938 2018-02-01
KR20180012942 2018-02-01
KR1020190001981A KR102732845B1 (en) 2018-02-01 2019-01-07 Manufacturing Method for Natural Killer Cells
KR1020190001983A KR102765799B1 (en) 2018-02-01 2019-01-07 Composition for Anti-cancer Comprising CD56+ Natural Killer Cells
PCT/US2019/016076 WO2019152663A1 (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer

Publications (1)

Publication Number Publication Date
SG11202007221QA true SG11202007221QA (en) 2020-08-28

Family

ID=68465207

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007221QA SG11202007221QA (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer

Country Status (15)

Country Link
US (4) US10590385B2 (en)
EP (1) EP3746095A4 (en)
JP (3) JP7268039B2 (en)
CN (2) CN115710576A (en)
AU (2) AU2019215034C1 (en)
BR (1) BR112020015512A2 (en)
CA (1) CA3089853A1 (en)
CL (1) CL2020002011A1 (en)
IL (1) IL276365B2 (en)
MX (2) MX386373B (en)
MY (2) MY199514A (en)
NZ (1) NZ766453A (en)
PH (1) PH12020551151A1 (en)
SA (1) SA520412566B1 (en)
SG (1) SG11202007221QA (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101520534B1 (en) * 2012-05-07 2015-05-21 고려대학교 산학협력단 Method for enrichment and expansion of natural killer cells derived from peripheral blood mononuclear cells
WO2018118907A1 (en) 2016-12-21 2018-06-28 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN114929249A (en) * 2019-11-29 2022-08-19 Nkmax有限公司 Methods of generating natural killer cells and compositions thereof
CN112626029B (en) * 2020-12-22 2022-12-20 深圳市赛欧细胞技术有限公司 Transgenic modified Daudi cell and preparation method and application thereof
KR20220160479A (en) * 2021-05-27 2022-12-06 (주)에스엠티바이오 Natural killer cells for treating neuroendocrine tumor
WO2024036226A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells
CN117122612B (en) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 Application of peripheral blood mononuclear cells in preparation of medicines for treating/preventing Alzheimer disease
CN116904397B (en) * 2023-09-04 2023-12-26 山东德升细胞治疗工程技术有限公司 Preparation and application of extracellular vesicles of NK cells

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320906C (en) 1986-06-04 1993-08-03 Daniel R. Twardzik Interleukin-2 induced antineoplastic peptide
JPH04503607A (en) 1989-02-24 1992-07-02 イムノセラピューティックス・インコーポレイテッド Immobilized cytokines
GR1001034B (en) 1989-07-21 1993-03-31 Ortho Pharma Corp METHOD OF CONTROL OF THE MULTIPLICATOR OF REGIONAL BLOOD.
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
WO1998005795A1 (en) 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19813759C1 (en) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Inducing a natural killer cell immune response ex vivo
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
WO2002097070A1 (en) 2001-05-30 2002-12-05 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
EP2380633A1 (en) 2002-06-07 2011-10-26 ZymoGenetics, Inc. Use of IL-21 in cancer
US7078041B2 (en) 2002-07-18 2006-07-18 University Of Washington Rapid, efficient purification of HSV-specific T-lymphocytes and HSV antigens identified via same
US20050191743A1 (en) 2002-10-03 2005-09-01 Wu J.H. D. Three-dimensional peripheral lymphoid organ cell cultures
JP4033390B2 (en) 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 Immortalized natural killer cell line
US20090297471A1 (en) 2004-05-28 2009-12-03 Mayo Foundation For Medical Education And Research Methods For Autologous Stem Cell Transplantation
US20090104170A1 (en) 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
JP5138380B2 (en) 2004-11-24 2013-02-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Methods for increasing immune responses in animals
DK1863905T3 (en) 2005-03-17 2016-04-04 Ucl Business Plc PROCEDURE FOR ACTIVATING NATURAL KILLER CELLS USING VITRO TUMOR CELL PREPARATIONS
ATE513903T1 (en) 2005-07-01 2011-07-15 Txcell S A PRODUCTION OF FOOD OR AUTO-ANTIGEN SPECIFIC TR1 CELLS FROM LEUKOCYTES OR PBMC
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
PT1941027E (en) 2005-09-28 2014-10-09 Ipd Therapeutics B V Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics.
AU2007223093A1 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
US8153120B2 (en) 2007-03-22 2012-04-10 Dendreon Corporation Methods for inducing a natural killer (NK) cell-mediated immune response and for increasing NK cell activity
PL2142642T3 (en) 2007-03-27 2017-10-31 Ipd Therapeutics B V Methods and means for stem cell proliferation and subsequent generation and expansion of progenitor cells, as well as production of effector cells as clinical therapeutics
KR100902340B1 (en) 2007-08-02 2009-06-12 한국생명공학연구원 Natural killer cell differentiation and differentiation method comprising BC-1 or IL-211 as active ingredients
US8727132B2 (en) 2007-12-07 2014-05-20 Miltenyi Biotec Gmbh Sample processing system and methods
KR101133185B1 (en) 2008-07-29 2012-04-06 서울대학교병원 Method for Proliferating Natural Killer cell
KR101077912B1 (en) * 2008-10-24 2011-10-31 주식회사 메디셀 A method for effective expansion and differentiation of NK cells from Cord Blood
US8372642B2 (en) 2009-02-27 2013-02-12 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
CN102428173B (en) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Expansion of NK cells
TW201127959A (en) 2010-02-12 2011-08-16 Ivy Life Sciences Co Ltd Method of producing immune killer cell
WO2011103882A1 (en) 2010-02-24 2011-09-01 Ingo Schmidt-Wolf Method for the generation of a cik cell and nk cell population
JP5996533B2 (en) 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション How to generate natural killer cells
KR101145391B1 (en) 2010-08-16 2012-05-15 고려대학교 산학협력단 A method for expansion of NK cells from Peripheral Blood
TWI439275B (en) 2010-12-31 2014-06-01 Glory Biomedical Co Ltd An ex vivo method for expanding human natural killer cells
KR20120093002A (en) 2011-02-14 2012-08-22 (주)에이티젠 Method for diagnosing cancer and diagnosis kit using measurement of nk cell activity
PL2686421T3 (en) 2011-03-18 2021-05-31 Glycostem Therapeutics B.V. Generation of nk cells and nk-cell progenitors
JP5572863B2 (en) * 2011-06-24 2014-08-20 国立大学法人九州大学 Method for amplifying NK cells
ES2652666T3 (en) 2011-12-22 2018-02-05 Mogam Biotechnology Institute Production process of natural cytolytic lymphocytes, natural cytolytic lymphocytes produced in this way and composition for the treatment of cancers and infectious diseases containing them
CA2864283C (en) 2012-02-08 2020-11-03 Jan Spanholtz Ex vivo nk cell differentiation from cd34+ hematopoietic cells
US9260696B2 (en) 2012-04-24 2016-02-16 Dan S. Kaufman Method for developing natural killer cells from stem cells
KR101520534B1 (en) * 2012-05-07 2015-05-21 고려대학교 산학협력단 Method for enrichment and expansion of natural killer cells derived from peripheral blood mononuclear cells
FI3578201T3 (en) 2012-06-28 2023-05-05 Univ Of Central Florida Research Foundation Incorporated METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLS
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP5856025B2 (en) 2012-08-02 2016-02-09 阿部　博幸 Methods for obtaining monocytes or NK cells
CN102988415B (en) 2012-08-15 2014-11-19 中航（宁夏）生物有限责任公司 Industrial production of natural killer cells (NK) and injections from human allogeneic nucleated cells
AU2013349706B2 (en) 2012-11-21 2019-08-22 Assistance Publique - Hopitaux De Paris Methods for determining the risk of acute graft versus host disease
US10160952B2 (en) 2013-01-15 2018-12-25 Hiroyuki Abe Method for manufacturing an immune cell-containing composition, and a cancer-treating composition
JP2016506968A (en) * 2013-02-05 2016-03-07 アントフロゲネシス コーポレーション Placenta-derived natural killer cells
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
KR20150145260A (en) 2013-04-19 2015-12-29 싸이튠 파마 Cytokine derived treatment with reduced vascular leak syndrome
EP3057986B1 (en) 2013-10-17 2017-12-27 National University of Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
WO2015100495A1 (en) 2014-01-03 2015-07-09 FullHope Biomedical Co., Ltd. Modified natural killer cells, compositions and uses thereof
WO2015125113A1 (en) 2014-02-21 2015-08-27 Dr. Reddy's Laboratories Limited Method of culturing high cell density pbmc's
US20170073637A1 (en) 2014-03-07 2017-03-16 Institut National De La Sante Et De Recherche Medicale (Inserm) Pooled nk cells from ombilical cord blood and their uses for the treatment of cancer and chronic infectious disease
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
KR102211120B1 (en) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 Modified natural killer cells and uses thereof
KR102441940B1 (en) 2014-06-11 2022-09-08 폴리바이오셉트 게엠베하 Proliferation of Lymphocytes for Active Cellular Immune Therapy Using Cytokine Compositions
JP2016008198A (en) 2014-06-24 2016-01-18 国立大学法人名古屋大学 Treatment of interstitial cystitis
JP2017525340A (en) 2014-07-07 2017-09-07 ターガザイム，アイエヌシー． Production and cryopreservation of fucosylated cells for therapeutic use
JP2016077185A (en) 2014-10-14 2016-05-16 学校法人 聖マリアンナ医科大学 PRODUCTION METHOD AND MEDICINE OF γδT CELLS
SG11201703237VA (en) 2014-11-19 2017-06-29 Axon Neuroscience Se Humanized tau antibodies in alzheimer's disease
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
HK1246180A1 (en) 2014-12-31 2018-09-07 Celgene Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
WO2016122014A1 (en) 2015-01-27 2016-08-04 한국생명공학연구원 Method for mass-producing natural killer cells and use of natural killer cells obtained by the method as anticancer agent
CN104705291A (en) 2015-04-03 2015-06-17 广州赛莱拉干细胞科技股份有限公司 Mononuclear cell frozen stock solution of cord blood, application and preparation method
GB201509202D0 (en) 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
WO2016209021A1 (en) 2015-06-24 2016-12-29 주식회사 차바이오텍 Method for proliferating natural killer cells and composition for proliferating natural killer cells
KR101851270B1 (en) 2015-07-10 2018-04-25 고려대학교 산학협력단 Method of expanding nk cell and composition for culturing
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
EP4424322A3 (en) 2015-12-17 2025-04-16 Novartis AG Antibody molecules to pd-1 and uses thereof
CN105524880A (en) 2016-01-27 2016-04-27 上海润泉生物技术有限公司 Construction method of immune cell bank
CN107267454B (en) 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 In-vitro amplification method of cord blood NK cells, kit and application thereof
WO2017188790A1 (en) * 2016-04-29 2017-11-02 고려대학교 산학협력단 Method for proliferating and culturing immune cells by using hypoxic conditions
NZ747910A (en) * 2016-05-07 2023-02-24 Celularity Inc Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
WO2018022646A1 (en) 2016-07-25 2018-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing modified natural killer cells and methods of use
AU2017340633B2 (en) 2016-10-05 2024-01-11 University Of Central Florida Research Foundation, Inc. Methods and compositions related to NK cell and anti-PDL1 cancer therapies
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
WO2018118907A1 (en) 2016-12-21 2018-06-28 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
KR101948534B1 (en) 2017-04-20 2019-02-15 주식회사 이뮤니스바이오 Mass Propagation Method Of NK Cells By Controlling The Density Of Cells
KR102460173B1 (en) 2017-05-26 2022-10-31 주식회사 지씨셀 Culturing method of natural killer cells using transformed T cells
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation Expansion of immune cells with interleukin-2 inducible t cell kinase inhibiting compounds
IL322312A (en) 2017-08-03 2025-09-01 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
WO2019046440A1 (en) 2017-08-29 2019-03-07 Flaask, Llc Compositions and methods for cognitive, immune and digestive support in patients with autism spectrum disorder
CN107970258B (en) 2017-11-20 2020-11-10 英普乐孚生物技术(上海)有限公司 Chimeric antigen receptor T cell preparation
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102765799B1 (en) 2018-02-01 2025-02-13 주식회사 엔케이맥스 Composition for Anti-cancer Comprising CD56+ Natural Killer Cells
WO2019152663A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102732845B1 (en) 2018-02-01 2024-11-25 주식회사 엔케이맥스 Manufacturing Method for Natural Killer Cells
DK3755347T3 (en) 2018-02-21 2025-08-04 Univ Texas Universal antigen presenting cells and uses thereof
WO2019168222A1 (en) 2018-02-28 2019-09-06 주식회사 제넨셀 Culture medium composition for culturing of anti-cancer activated lymphocytes derived from peripheral blood mononuclear cells and method for culturing anti-cancer activated lymphocytes using same
KR102693317B1 (en) 2018-03-13 2024-08-07 푼다시온 파라 라 인베스티가시온 바이오메디카 델 호스피탈 우니베르시타리오 라 파즈 Anti-CXCR4 Antibody in Combination with Activated and Expanded Natural Killer Cells for Cancer Immunotherapy
EP3539552A1 (en) 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
WO2019182392A1 (en) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 Method for producing natural killer cells
KR20210005240A (en) 2018-05-03 2021-01-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blocking
US12304962B2 (en) 2018-05-30 2025-05-20 Glycostem Therapeutics B.V. CAR NK cells
WO2020006139A1 (en) 2018-06-27 2020-01-02 The George Washington University Targeting stat sumoylation to enhance immune responses
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN109294985B (en) 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 Culture medium system for NK cell in-vitro amplification and NK cell in-vitro amplification method
BR112021008461A2 (en) 2018-11-08 2021-08-03 Gammadelta Therapeutics Ltd methods for isolating and expanding cells
WO2020101361A1 (en) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 Method for culturing cord blood-derived natural killer cells using transformed t-cells
CN111205361B (en) 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 Interleukin 21 protein (IL21) mutant and application thereof
EP3656851A1 (en) 2018-11-23 2020-05-27 Technische Universität Dresden Artificial hla-positive feeder cell lines for nk cells and uses thereof
US20220047635A1 (en) 2018-11-26 2022-02-17 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
EP4471129A3 (en) 2018-11-29 2025-02-19 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
MX2021008147A (en) 2019-01-07 2021-08-11 Inhibrx Inc POLYPEPTIDES INCLUDING MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF.
WO2020172328A1 (en) 2019-02-20 2020-08-27 Rutgers, The State University Of New Jersey Expansion of natural killer and chimeric antigen receptor-modified cells
CU24712B1 (en) 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois METHOD FOR THE EXPANSION AND DIFFERENTIATION OF T LYMPHOCYTES AND NK CELLS IN ADOPTIVE TRANSFER THERAPIES
MX2021011816A (en) 2019-03-29 2021-10-22 Univ Texas METHODS FOR THE PRODUCTION OF CAR-NK CELLS AND THEIR USE.
EP3989984A4 (en) 2019-06-25 2024-05-22 City of Hope TREATMENT OF PDL1-POSITIVE TUMORS WITH NK CELLS
CN114929249A (en) 2019-11-29 2022-08-19 Nkmax有限公司 Methods of generating natural killer cells and compositions thereof
US20250195574A1 (en) 2022-06-02 2025-06-19 Nkmax Co., Ltd. Method for reduction of immune checkpoint therapy related adverse events
WO2024015822A1 (en) 2022-07-12 2024-01-18 Nkmax Co., Ltd. Method of treating parkinson's disease with expanded natural killer cells
KR20250044781A (en) 2022-08-10 2025-04-01 주식회사 엔케이맥스 Treatment of Alzheimer's disease using expanded natural killer cells
WO2024036226A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells

Also Published As

Publication number Publication date
NZ766453A (en) 2022-02-25
JP2022000060A (en) 2022-01-04
IL276365A (en) 2020-09-30
CN115710576A (en) 2023-02-24
EP3746095A1 (en) 2020-12-09
MX386373B (en) 2025-03-18
AU2021266198A1 (en) 2021-12-02
CN111757745B (en) 2022-11-04
IL276365B1 (en) 2023-06-01
US20250059510A1 (en) 2025-02-20
US10590385B2 (en) 2020-03-17
US12098388B2 (en) 2024-09-24
MX2021004682A (en) 2021-06-04
US20210032597A1 (en) 2021-02-04
AU2019215034A1 (en) 2020-08-27
MY197176A (en) 2023-05-30
US11066644B2 (en) 2021-07-20
AU2021266198B2 (en) 2024-12-19
RU2020128764A (en) 2022-03-01
MX2020008039A (en) 2021-09-20
US20200172869A1 (en) 2020-06-04
AU2019215034B2 (en) 2021-08-19
CA3089853A1 (en) 2019-08-08
JP7669434B2 (en) 2025-04-28
AU2019215034C1 (en) 2022-01-06
US20190345449A1 (en) 2019-11-14
EP3746095A4 (en) 2021-04-21
SA520412566B1 (en) 2025-05-11
IL276365B2 (en) 2023-10-01
RU2020128764A3 (en) 2022-03-01
MY199514A (en) 2023-11-02
JP7339309B2 (en) 2023-09-05
JP2023153361A (en) 2023-10-17
JP2021506333A (en) 2021-02-22
CN111757745A (en) 2020-10-09
BR112020015512A2 (en) 2021-01-26
PH12020551151A1 (en) 2021-09-01
JP7268039B2 (en) 2023-05-02
CL2020002011A1 (en) 2021-02-12

Similar Documents

Publication Publication Date Title
IL276365A (en) Method of producing natural killer cells and composition for treating cancer
ZA202006627B (en) Methods and compositions for treating cancer
IL313807A (en) Claudin18 antibodies and methods of treating cancer
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
IL286350A (en) Compositions and methods for treating cancer
IL288914A (en) Compositions and methods for treating cancer
MX2018011114A (en) Crispr/cas-related methods and compositions for treating beta hemoglobinopathies.
IL285631A (en) Methods for producing autologous t cells useful for cancer treatment and compositions thereof
SG11202013239RA (en) Composition and method for treating pain
ZA202104870B (en) Methods and compositions for treating cancer
EP3778649A4 (en) Method and composition for treating tumors
SG11202107904PA (en) Compositions and methods for stimulating natural killer cells
SG11202012435UA (en) Compositions and methods for treating cancer
IL275767A (en) Compositions and methods for treating metabolic diseases
SG11202109336UA (en) Methods and compositions for treating cancer
IL287210A (en) Method of treating tumours
IL287982A (en) Compositions and methods for treating cancer
IL278978A (en) Compositions and methods for treatment of psoriasis
IL284480A (en) Composition and methods for treatment of primary ciliary dyskinesia
IL276203A (en) Compositions and methods of treating cancer
EP4055040A4 (en) Compositions and methods for treatment of cancer with lekti
IL289811A (en) Method of treating cancer
IL286153A (en) Methods and compositions for treating cancer
EP3773585A4 (en) Compositions and methods for treating cancer
SG11202107017TA (en) Methods of treating cancer